Investors of LifeMD, Inc. Encouraged to Inquire About Securities Class Action Investigation

LifeMD, Inc. investors are encouraged to inquire about a securities class action investigation due to allegations of misleading business information. The Rosen Law Firm is preparing a class action seeking recovery of investor losses. If you purchased LifeMD securities, you may be entitled to compensation without payment of any out-of-pocket fees or costs. Contact Phillip Kim, Esq. for information on the class action.

LifeMD, Inc. (LFMD) investors are encouraged to inquire about a securities class action investigation due to allegations of misleading business information. The Rosen Law Firm is preparing a class action seeking recovery of investor losses. If you purchased LifeMD securities, you may be entitled to compensation without payment of any out-of-pocket fees or costs. Contact Phillip Kim, Esq. for information on the class action.

On August 5, 2025, after the market closed, LifeMD reported its financial results for the second quarter of 2025. In this announcement, LifeMD revised its guidance, stating that it was expecting total revenue in the range of $250 to $255 million, compared to previous guidance of $268 to $275 million. This revision led to a significant drop in LifeMD's stock price, plummeting 44.8% on August 6, 2025 [1].

The Rosen Law Firm, a global investor rights law firm, is investigating potential securities claims on behalf of LifeMD shareholders. The firm is preparing a class action seeking recovery of investor losses, with no out-of-pocket fees or costs for participants [1].

LifeMD's stock price saw a slight rebound on Wednesday, August 22, 2025, following a bullish note from KeyBanc Capital Markets. The bank cited proprietary cardholder data showing a "meaningful uptick" in telehealth revenue for LifeMD and its RexMD business, attributed to increased demand for telehealth services [2].

Despite the recent earnings shock and stock plunge, LifeMD's cash reserves and AI-driven operational improvements suggest potential for recovery. The telehealth sector's high-growth potential remains attractive to investors, despite regulatory risks and operational challenges [2].

Investors are advised to remain vigilant and conduct thorough due diligence before making investment decisions in the telehealth sector. For more information on the class action, contact Phillip Kim, Esq. at the Rosen Law Firm [1].

References:
[1] https://www.morningstar.com/news/pr-newswire/20250822dc57608/lfmd-investor-news-rosen-law-firm-encourages-lifemd-inc-investors-to-inquire-about-securities-class-action-investigation-lfmd
[2] https://www.ainvest.com/news/lifemd-shares-rise-keybanc-forecasts-increased-telehealth-revenue-2508/